Takeda发射FRUZAQLA,这是日本对结肠癌的新口服癌症治疗。 Takeda launches FRUZAQLA®, a new oral cancer treatment for colorectal cancer, in Japan.

(fruquinitinib)在日本推出FRUZAQLA(fruquintinib), 以治疗转移性直肠癌, 标志着日本十年来首次通过新的口服定向治疗, HUTCHMED announced Takeda's launch of FRUZAQLA® (fruquintinib) in Japan for treating metastatic colorectal cancer, marking the first novel oral targeted therapy approved in Japan for this condition in over a decade. 该药物也在美国、欧盟和其他几个国家获得批准。 The drug has also been approved in the US, EU, and several other countries. FRUZAQLA是VEGF受体的口服抑制剂,在临床试验中表现出一贯的好处。 FRUZAQLA® is an oral inhibitor of VEGF receptors and has shown consistent benefits in clinical trials.